Moleculin market research shows oncologists likely to prescribe Annamycin in relapsed/refractory AML

Moleculin Biotech, Inc.

Moleculin Biotech, Inc.

MBRX

0.00
  • Moleculin Biotech disclosed results from an independent market assessment on Annamycin in relapsed or refractory acute myeloid leukemia.
  • Findings were presented now, not flagged for a future conference or publication.
  • Surveyed oncologists signaled strong intent to prescribe, citing deep remissions, transplant-bridging potential, broad use across mutation status.
  • Reduced cardiotoxicity was highlighted as a key differentiator, supporting potential repeat dosing, including perceived relevance in pediatric settings.
  • Payer interviews indicated support for reimbursement, viewing the drug as addressing a major unmet need with a favorable efficacy-safety profile.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606050829PRIMZONEFULLFEED9732247) on June 05, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.